Increased frequency and clinical significance of myeloid- derived suppressor cells in human colorectal carcinoma
AIM: To investigate the frequency and clinical signifi- cance of the myeloid-derived suppressor cells (MDSC) in human colorectal carcinoma (CRC). METHODS: Samples of peripheral blood and tumor tis- sue from 49 CRC patients were analyzed. Mononuclear cells were isolated by FicolI-Hypaque density grad...
Gespeichert in:
Veröffentlicht in: | World journal of gastroenterology : WJG 2012-07, Vol.18 (25), p.3303-3309 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | AIM: To investigate the frequency and clinical signifi- cance of the myeloid-derived suppressor cells (MDSC) in human colorectal carcinoma (CRC). METHODS: Samples of peripheral blood and tumor tis- sue from 49 CRC patients were analyzed. Mononuclear cells were isolated by FicolI-Hypaque density gradient centrifugation and were subjected to a flow cytometry- based immunophenotypic analysis. RESULTS: A considerable increase in the percentage of CD33+HLA-DR MDSCs was observed in the periph- eral blood (1.89% :1= 0.75%) and tumor tissues (2.99%±1.29%) of CRC patients as compared with that in theperipheral blood of healthy controls (0.54%±0.35%). This expanded CD33+HLA-DR subset exhibited imma- ture myeloid cell markers, but not lineage markers, and showed up-regulation of CD18/CD11b expression as compared with the MDSCs from healthy donors. Fur- ther studies showed that the MDSC proportion in CRC peripheral blood was correlated with nodal metastasis (P = 0.023), whereas that in tumor tissues was cor- related with nodal/distant metastasis (P = 0.016/P = 0.047) and tumor stage (P = 0.028), suggesting the involvement of MDSCs in CRC tumor development. CONCLUSION: Characterization of MDSCs in CRC sug- gests the clinical significance of circulating and tumor- infiltrating MDSCs and may provide new insights into the CRC immunotherapy targeting MDSCs. |
---|---|
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.v18.i25.3303 |